NCT04364997 - Study of Desvenlafaxine in Treating Major Depressive Disorder. | Biotech Hunter

Enrollment

420

Participants

Timeline

Start Date

June 18, 2020

Primary Completion Date

September 22, 2021

Study Completion Date

September 22, 2021

Conditions

Major Depressive Disorder

Interventions

DRUG

Desvenlafaxine Succinate Sustained-Release Tablet , Duloxetine Hydrochloride Enteric-coated Capsule Placebo

Desvenlafaxine Succinate Sustained-Release Tablet 50 mg+Duloxetine Hydrochloride Enteric-coated Capsule Placebo 60 mg orally once daily for 8 weeks.

DRUG

Desvenlafaxine Succinate Sustained-Release Tablet Placebo, Duloxetine Hydrochloride Enteric-coated Capsule

Desvenlafaxine Succinate Sustained-Release Tablet Placebo 50mg +Duloxetine Hydrochloride Enteric-coated Capsule 60mg orally once daily for 8 weeks,

DRUG

Duloxetine Hydrochloride Enteric-coated Capsule Placebo

Duloxetine Hydrochloride Enteric-coated Capsule Placebo 30 mg orally once daily for 1 week after 8-weeks treatment.

DRUG

Duloxetine Hydrochloride Enteric-coated Capsule

Duloxetine Hydrochloride Enteric-coated Capsule 30mg orally once daily for 1 week after 8-weeks treatment.

Trial Locations (1)

Beijing Anding Hospital, Beijing

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY